McKesson Corporation delivered strong fiscal Q3 2026 results with revenue of $106.2 billion (up 11% YoY) and adjusted EPS of $9.34 (up 16% YoY). The company raised its full-year EPS guidance to $38.80-$39.20, representing 17-19% growth, driven by momentum across oncology, biopharma services, and North American distribution. Key performance drivers included 37% revenue growth in the Oncology and Multispecialty segment, 9% revenue growth in North American Pharmaceutical segment, and 18% operating profit growth in Prescription Technology Solutions. The company completed the divestiture of its Norwegian operations and continues progressing toward the separation of its medical-surgical business, targeting an IPO by H2 2027. McKesson returned $781 million to shareholders during the quarter through share repurchases ($680 million) and dividends ($101 million).
| Metric | Value | Change |
|---|---|---|
| Revenue | $106.2 billion | +11% |
| Adjusted EPS | $9.34 | +16% |
| Gross Profit | $3.7 billion | +10% |
| Operating Profit | $1.7 billion | +13% |
| Free Cash Flow (Quarter) | $1.1 billion | N/A |
| Free Cash Flow (TTM) | $9.6 billion | N/A |
| Share Repurchases | $680 million | N/A |
| Dividend Payments | $101 million | N/A |
| North American Pharmaceutical Revenue | $88.3 billion | +9% |
| Oncology and Multispecialty Revenue | $13 billion | +37% |
| Prescription Technology Solutions Revenue | $1.5 billion | +9% |
| GLP-1 Distribution Revenue | $14 billion | +26% |
McKesson's Oncology and Multispecialty segment demonstrated exceptional growth with revenues increasing 37% to $13 billion and operating profit increasing 57% to $366 million. This growth was driven by strong provider growth, expanded specialty distribution, and contributions from acquisitions (Prism Vision and Core Ventures). The US Oncology Network now has approximately 3,400 providers, and Prism Vision brings together over 200 providers in retina and ophthalmology. Management noted that excluding acquisitions, organic operating profit increased 15%, highlighting the segment's strong underlying performance. This strategic focus on oncology positions McKesson to benefit from the anticipated growth in precision medicine and innovative therapies.
The Biopharma Services business continues to expand with 50 new programs across 43 unique brands added to the platform during the quarter. Management emphasized their investment in capabilities to simplify electronic patient enrollment processes, reducing time from days or weeks to sometimes just minutes. They're currently digitizing enrollment for more than 1,600 specialty medications. This strategic focus on patient access and affordability solutions creates a competitive moat and positions McKesson to benefit from the accelerating pace of drug innovation.
McKesson is making significant investments in technology and automation across the enterprise. In the Prescription Technology Solutions segment, they've implemented AI chat tools to handle customer inquiries related to the Drug Supply Chain Security Act, preventing 75% of inquiries from being escalated. In their annual verification season, each full-time employee is successfully supporting 120 more patients than last year, representing a meaningful productivity increase. These technology investments are driving operational efficiencies and improving customer experience while creating scalability for future growth.
GLP-1 distribution continues to be a significant growth driver with revenues of $14 billion in the quarter, up $3 billion or 26% compared to the prior year, with sequential revenue growth of 7%. Management noted that they anticipate continued growth of GLP-1 medications, though it may vary from quarter to quarter. This positions McKesson to benefit from one of the most significant pharmaceutical trends in recent years, though management appropriately cautioned about potential variability.
McKesson is progressing toward the separation of its medical-surgical business, with transition service agreements now in place across the enterprise. They're tracking toward a timeline of an IPO by the second half of calendar 2027, subject to market conditions and regulatory approvals. This strategic portfolio optimization will allow McKesson to focus on its higher-growth businesses in oncology, multispecialty, and biopharma services while potentially unlocking value for shareholders.
The company completed the divestiture of its Norwegian business in January, marking the final step in its full exit from the European region. This completes a multi-stage initiative executed over four years. Management noted that with the experience gained from this exit, they're confident in their ability to focus on current portfolio actions, optimizing assets and accelerating growth for the enterprise. This strategic refocusing on North American markets allows for more targeted capital allocation.
McKesson continues to demonstrate strong capital allocation discipline, returning $781 million to shareholders during the quarter ($680 million in share repurchases and $101 million in dividends). For the trailing twelve months, the company delivered free cash flow of $9.6 billion. Management anticipates repurchasing approximately $2 billion of shares in fiscal 2026 while maintaining an investment-grade credit rating. This balanced approach to capital deployment supports both growth investments and shareholder returns.
The company is investing in expanding refrigerated capacity across its network, with a multiyear plan that is halfway complete. Once finished, this expansion will increase refrigeration capacity at many forward distribution centers by more than 50%, strengthening their ability to support temperature-sensitive products. This infrastructure investment positions McKesson to handle the growing specialty pharmaceutical market and demonstrates their commitment to operational excellence.
The Medical-Surgical Solutions segment showed weakness with revenues increasing only 1% compared to the prior year and operating profit decreasing 10% to $265 million. Management attributed this to lower volumes across physician office settings and lower incidence of seasonal illness. While this segment is being prepared for separation, the underperformance could impact near-term profitability and may indicate challenges in the physician office market that could persist even after the separation.
Management noted soft illness season demand in fiscal Q3, with December illness severity levels peaking based on CDC data. They highlighted that variability in timing, severity, and duration of each illness season can drive variation and meaningfully affect results on both a quarterly and annual basis. This creates uncertainty for the Medical-Surgical segment and could impact the Prescription Technology Solutions segment which is sensitive to utilization trends.
While McKesson is raising guidance, management noted that GLP-1 medication growth may vary from quarter to quarter. Given that GLP-1 distribution revenues were $14 billion in the quarter (up 26% YoY), any significant deceleration or variability in this category could impact overall growth rates. Management appropriately cautioned about this variability, but it remains a key risk factor given the magnitude of these revenues.
The company anticipates fiscal fourth quarter technology investments to be an approximate $0.05 incremental cost compared to the prior year. While these investments are necessary for long-term growth, they create a near-term headwind to profitability. Management also noted that revenue and operating profit trends in the Prescription Technology Solutions segment are not linear and can vary from quarter to quarter due to multiple factors including utilization trends, timing of new product launches, and program support requirements.
Management discussed navigating a complex regulatory environment including the Inflation Reduction Act's Medicare Part D price changes that went into effect in January. While they expressed confidence in their ability to navigate these changes, they noted that policy proposals like MFN (Most Favored Nation) and changes to gross-to-net calculations could impact the business. The dynamic policy landscape creates uncertainty for future operations.
The Prescription Technology Solutions segment faces multiple variables that could impact quarterly performance, including utilization trends, timing and trajectory of new product drug launches, evolution of product program support requirements, product delays and supply chain dynamics, payer utilization and formulary requirements, and the annual verification programs. This complexity creates potential for quarterly volatility and makes forecasting more challenging.
While management expressed confidence in the separation of the medical-surgical business, they noted that the IPO timeline of second half of calendar 2027 is subject to market conditions and regulatory approvals. Any delays or changes to this timeline could impact the company's strategic focus and capital allocation plans. Additionally, the separation process itself requires significant management attention and resources.
Overall: Management displayed high confidence throughout the call, emphasizing the strength and durability of their business model. Both Brian Tyler and Britt Vitalone spoke with conviction about the company's strategic execution and positive momentum across key segments. Their tone remained consistently positive during both prepared remarks and Q&A, with detailed responses to analyst questions that included specific metrics and examples.
Confidence: HIGH - Management demonstrated high confidence through specific guidance increases, detailed performance metrics, and clear articulation of strategic priorities. They provided concrete examples of successful technology implementations and acquisition integrations.
$38.80-$39.20 (17-19% growth)
12-16%
13-17%
$4.4-$4.8 billion
Approximately $2 billion
10-14%
8-12%
29-33%
51-55%
9-13%
14-18%
2-6%
Hedging & Uncertainty: Management used relatively limited hedging language throughout the call, demonstrating confidence in their outlook and execution. When discussing uncertainties, they typically provided specific context and mitigating factors. For example, when addressing GLP-1 variability, Britt Vitalone stated, 'In the core distribution business, we anticipate continued growth of GLP-1 medication. However, we anticipate this growth may vary from quarter to quarter.' When discussing the medical-surgical segment, Brian Tyler noted, 'We're closely tracking the development of the current illness season. We've observed soft illness season demand in our fiscal third quarter.' This balanced approach acknowledges uncertainties while maintaining confidence in the overall strategy. The most notable hedging appeared around regulatory risks, where management used phrases like 'we continue to think that the implications for McKesson Corporation are quite navigable' rather than more definitive statements.
"Today's results once again demonstrate the strength and durability of our business." - Brian Tyler, CEO
"The consistency of this performance gives us the confidence to raise full-year EPS guidance to a range of $38.80 to $39.20." - Brian Tyler, CEO
"Our balance sheet remains a significant source of strength, underpinned by strong cash generation and disciplined capital allocation." - Britt Vitalone, CFO
"We're energized by the tremendous opportunity to bring novel therapies to patients and to enable real-world impact." - Brian Tyler, CEO
"These insights underscore the strength of our platform and the opportunity to leverage our solutions to deepen provider and biopharma partnerships." - Brian Tyler, CEO
"We're positioning the business for long-term growth by investing in capabilities that meet the evolving needs of our customers and the market." - Brian Tyler, CEO
"The consistency of our strategy, operational execution, and disciplined portfolio management led to outstanding long-term results." - Britt Vitalone, CFO
"Our financial strength and flexibility remain a competitive advantage, enabling us to invest for future growth while returning meaningful value to our shareholders." - Britt Vitalone, CFO
Analyst Sentiment: Analysts expressed generally positive sentiment with several congratulating management on strong results. Questions focused on understanding the drivers of growth, particularly in technology investments, margin improvement, and segment performance. Some analysts sought clarification on guidance ranges and potential variability in key growth areas like GLP-1s.
Management Responses: Management provided detailed, data-driven responses to analyst questions, often citing specific metrics and examples to support their points. They demonstrated deep knowledge of the business and confidence in their strategy. When addressing concerns about variability or potential risks, they provided context and mitigating factors while maintaining an overall positive tone.
Technology and automation investments driving efficiency improvements, particularly in annual verification processes and DSCSA compliance.
Margin improvement drivers in the Oncology and Multispecialty segment, including contributions from acquisitions and organic growth.
North American Pharmaceutical segment performance and guidance, including the impact of specialty distribution growth and operational efficiency.
Regulatory environment impacts, including the Inflation Reduction Act, MFN proposals, and gross-to-net calculations.
GLP-1 market trends and their impact on McKesson's business, including prior authorization patterns and growth sustainability.
Capital allocation priorities and the balance between internal investments, acquisitions, and shareholder returns.
Integration progress and performance of recent acquisitions, particularly Prism Vision and Florida Cancer Specialists.
Prescription Technology Solutions segment performance and growth drivers beyond GLP-1s.
Pricing dynamics with pharmaceutical manufacturers and the impact of brand drug price decreases.
McKesson Corporation delivered exceptional fiscal Q3 2026 results, demonstrating the strength of its diversified business model and successful execution of strategic priorities. The company's 11% revenue growth and 16% EPS growth, coupled with a guidance raise, highlight the momentum across key segments. The Oncology and Multispecialty segment's 37% revenue growth and 57% operating profit growth demonstrate the success of McKesson's strategic focus on high-growth areas. The Biopharma Services business continues to expand with 50 new programs added during the quarter, positioning the company to benefit from accelerating drug innovation. Technology and automation investments are driving operational efficiencies and improving customer experience, creating a competitive advantage. The company's strong balance sheet, with $9.6 billion in trailing twelve-month free cash flow, supports disciplined capital allocation including share repurchases and dividends. While the Medical-Surgical segment faces near-term challenges, the planned separation will allow McKesson to focus on its higher-growth businesses. The completion of the European exit further streamlines the portfolio. Despite potential variability in GLP-1 growth and regulatory headwinds, McKesson's diversified business model, scale advantages, and strategic positioning in high-growth areas support a positive long-term outlook. The company's ability to consistently deliver double-digit growth while returning significant capital to shareholders makes it an attractive investment opportunity.
Management discussed navigating policy changes including the Inflation Reduction Act's Medicare Part D price changes that went into effect in January. They also addressed potential impacts from proposed policies like MFN (Most Favored Nation) and changes to gross-to-net calculations. While management expressed confidence in their ability to navigate these changes, the dynamic policy landscape creates uncertainty for future operations.
GLP-1 distribution continues to be a significant growth driver with revenues of $14 billion in the quarter, up 26% year-over-year. Management noted continued growth in this category though with potential quarterly variability. The company is also seeing prior authorizations for newly launched oral GLP-1s, though it's early days for this product.
McKesson is experiencing strong growth in specialty distribution across multiple segments. The company is investing in expanding refrigerated capacity across its network to support temperature-sensitive products, positioning them to handle the growing specialty pharmaceutical market.
McKesson is leveraging technology and automation to drive efficiencies across the enterprise. They're implementing AI chat tools, digitizing patient enrollment processes, and using automation to improve productivity. These investments are creating operational efficiencies and improving customer experience while creating scalability for future growth.
Management noted soft illness season demand in fiscal Q3, with December illness severity levels peaking based on CDC data. They highlighted that variability in timing, severity, and duration of each illness season can drive variation and meaningfully affect results on both a quarterly and annual basis, particularly for the Medical-Surgical segment.